Review ArticlesSampling and Reporting of Inflammatory Bowel DiseaseBrown, Ian S. MBBS, FRCPA*,†; Liu, Cheng FRCPA*,†,‡; Miller, Gregory C. FRCPA*,† Author Information *Envoi Specialist Pathologists †Faculty of Medicine, University of Queensland ‡The Conjoint Gastroenterology Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, Qld, Australia The authors have no funding or conflicts of interest to disclose. Reprints: Ian S. Brown, MBBS, FRCPA, Envoi Specialist Pathologists, 5/38 Bishop Street, Kelvin Grove, Qld 4059, Australia (e-mail: [email protected]). All figures can be viewed online in color at www.anatomicpathology.com. Advances In Anatomic Pathology 29(1):p 25-36, January 2022. | DOI: 10.1097/PAP.0000000000000318 Buy Metrics Abstract Pathologists have an important and expanding role in the diagnosis and management of inflammatory bowel disease. This role includes the initial diagnosis of the disease, assessment of the response to treatment and the identification of short-term complications such as cytomegalovirus infection and long-term complications such as dysplasia. Furthermore, the assessment of resection specimens for complication of disease is important to determining the risk of subsequent disease or inflammation within an ileal pouch. Adequate sampling of the disease at endoscopy and from the surgical resection specimen is vital to determining the ultimate information that can be provided by the pathologist. This sampling is determined by the clinical scenario. Similarly, a standardized approach to reporting and synthesizing the histologic findings will improve patient management. This is best exemplified by the increasing interest in histologic activity indices, such as the Nancy index in ulcerative colitis, and in the standardized reporting for inflammatory bowel disease dysplasia recommended by the SCENIC international consensus. Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.